Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Staphylococcal Pathogens Assessed in Periprosthetic Joint Infections

By LabMedica International staff writers
Posted on 04 Nov 2016
Periprosthetic joint infections (PJI) are the main complication of knee and hip prosthetic arthroplasty and between 1% and 3% of patients undergoing prosthesis implantation are affected by these infections.

The characteristics of periprosthetic joint infection (PJI) due to Staphylococcus lugdunensis have been assessed and compared to the characteristics of PJI due to Staphylococcus aureus and Staphylococcus epidermidis. More...
S. lugdunensis is a coagulase-negative staphylococci (CoNS) that is considered part of the normal flora of human skin, as are other CoNS species.

Medical microbiologists at the Hôpital J. Ducuing (Toulouse, France) conducted a retrospective and descriptive study from 2000 to 2014, including patients from three orthopedic centers in the same area. Eighty-eight consecutive cases of monomicrobial staphylococcal PJI were analyzed; 28 due to S. lugdunensis, 30 to S. aureus, and 30 S. epidermidis. The diagnosis of PJI was established in the presence of one major criterion or two minor criteria: the major criteria were at least two positive periprosthetic cultures with phenotypically identical organisms, or a sinus tract communicating with the joint; minor criteria were a C-reactive protein (CRP) value greater than 10 mg/L and a histological analysis of periprosthetic tissue confirming a septic process.

For each suspected site, hard and soft tissue specimens were collected in sterile glass vials and articular fluid was inoculated into blood culture bottles. After inoculation into culture media, these were observed daily for microbial growth. Bacteriological criteria for a positive diagnosis of infection were the following: at least one positive sample for S. aureus-positive cultures; at least two positive samples for S. epidermidis- and S. lugdunensis-positive cultures. In the case of a positive culture, identification was performed by the Vitek 2 automated technique or the API Staph manual technique.

Clinical symptoms were more often reported in the S. lugdunensis group, and the median delay between surgery and infection was shorter for the S. lugdunensis group than for the S. aureus and S. epidermidis groups. As regards antibiotic susceptibility, the S. lugdunensis strains were susceptible to antibiotics and 61% of the patients could be treated with levofloxacin + rifampicin. The outcome of the PJI was favorable for 89% of patients with S. lugdunensis, 83% with S. aureus, and 97% with S. epidermidis. Nine unfavorable outcomes were reported in the total population.

The authors concluded that S. lugdunensis is classified as a CoNS, but the clinical features of S. lugdunensis PJI, the early aspect of the infection, and the relapses observed are similar to those in S. aureus PJI. Regarding the microbiological diagnosis, the species of CoNS in PJI must be identified precisely and treatment adapted to the antibiotic susceptibility, even if only one deep sample is positive in culture. The study was published in the October 2016 issue of the International Journal of Infectious Diseases.

Related Links:
Hôpital J. Ducuing



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.